From Jefferies to Edelweiss, here's how brokerages interpret HUL-GSK deal

Here is a quick look at how various brokerages interpret the contours of the HUL-GSK Consumer deal and its impact on the other players in the FMCG space

A day after Hindustan Unilever (HUL) said it was merging GlaxoSmithKline (GSK) Consumer Healthcare with itself in a transaction worth Rs 317 billion that triggered a rally in both counters on Monday, HUL and GSK Consumer gave up some of the gains on Tuesday. While HUL slipped nearly a per cent lower at Rs 1,811 levels on the NSE, GSK Consumer Healthcare, too, is trading marginally lower at Rs 7,524 levels.

Most brokerages have given a thumbs-up to the deal and maintain either a ‘hold’ or a ‘sector outperformer’ rating on HUL post the development. 

Thus far in the calendar year